Research into amyotrophic lateral sclerosis (ALS) is gaining momentum. According to Citeline, early-stage clinical activity surged from 28 new trials in 2023 to 60 in 2024, a remarkable increase for a disease long plagued by limited treatment options. Despite this progress, late-stage candidates remain scarce, with only a few phase 3 programs listed on ClinicalTrials.gov and reported on PharmaVoice.
One company aiming to change that landscape is MediciNova, which recently completed enrollment for a pivotal phase 2b/3 trial of MN-166 (ibudilast). The study builds on earlier findings suggesting the drug may slow disease progression—a critical goal in ALS care.
What Makes MN-166 Different?
Unlike therapies targeting single genetic mutations, MN-166 employs a dual-action mechanism. It combines neuroprotective and anti-inflammatory effects, inhibiting pathways such as macrophage migration inhibitory factor and TLR4—both linked to neuronal damage. This broad approach could offer benefits across diverse ALS patient populations.
Previous trials hinted at functional improvements: in one analysis, 21% of MN-166 patients showed better ALS rating scores versus 12% on placebo. The current study will assess outcomes using gold-standard measures like functional decline slope and survival, alongside innovative “responder analysis” to determine if progression can be halted.
A Long Road and a Lean Strategy
Originally approved in Japan for asthma, ibudilast later demonstrated promise in multiple sclerosis models. MediciNova acquired rights and expanded development into ALS, MS, and even addiction disorders. The company’s funding model—built on grants and partnerships rather than heavy market fundraising—has kept operations lean. With $340 million in cash, no debt, and a modest annual burn rate, MediciNova is positioned to sustain its programs without near-term financing.
The ALS trial is expected to conclude in August, with interim data possible earlier. While regulatory approval isn’t guaranteed, MediciNova is preparing for potential FDA submission, signaling cautious optimism for the ALS community.
